Patrick F Augustijns

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8423787/publications.pdf

Version: 2024-02-01

366 papers	19,416 citations	8755 75 h-index	19190 118 g-index
377 all docs	377 docs citations	377 times ranked	16211 citing authors

#	Article	IF	Citations
1	Supersaturating Drug Delivery Systems: The Answer to Solubility-Limited Oral Bioavailability?. Journal of Pharmaceutical Sciences, 2009, 98, 2549-2572.	3.3	778
2	Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. International Journal of Pharmaceutics, 2008, 364, 64-75.	5.2	611
3	Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. European Journal of Pharmaceutical Sciences, 2001, 12, 261-269.	4.0	370
4	In vitro models for the prediction of in vivo performance of oral dosage forms. European Journal of Pharmaceutical Sciences, 2014, 57, 342-366.	4.0	297
5	Histamine Receptor H1â€“Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology, 2016, 150, 875-887.e9.	1.3	263
6	Favipiravir at high doses has potent antiviral activity in SARS-CoV-2â^'infected hamsters, whereas hydroxychloroquine lacks activity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 26955-26965.	7.1	240
7	Ordered Mesoporous Silica Material SBA-15: A Broad-Spectrum Formulation Platform for Poorly Soluble Drugs. Journal of Pharmaceutical Sciences, 2009, 98, 2648-2658.	3.3	237
8	In vivo methods for drug absorption â€“ Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences, 2014, 57, 99-151.	4.0	226
9	The mechanisms of pharmacokinetic food-drug interactions â€“ A perspective from the UNGAP group. European Journal of Pharmaceutical Sciences, 2019, 134, 31-59.	4.0	224
10	Successful oral delivery of poorly water-soluble drugs both depends on the intraluminal behavior of drugs and of appropriate advanced drug delivery systems. European Journal of Pharmaceutical Sciences, 2019, 137, 104967.	4.0	222
11	Increasing the oral bioavailability of the poorly water soluble drug itraconazole with ordered mesoporous silica. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 223-230.	4.3	221
12	Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. European Journal of Pharmaceutical Sciences, 2008, 35, 383-396.	4.0	220
13	Physical State of Poorly Water Soluble Therapeutic Molecules Loaded into SBA-15 Ordered Mesoporous Silica Carriers: A Case Study with Itraconazole and Ibuprofen. Langmuir, 2008, 24, 8651-8659.	3.5	212
14	Evaluation of gastrointestinal drug supersaturation and precipitation: Strategies and issues. International Journal of Pharmaceutics, 2013, 453, 25-35.	5.2	212
15	Enhanced release of itraconazole from ordered mesoporous SBA-15 silica materials. Chemical Communications, 2007, , 1375.	4.1	202
16	A screening study of surface stabilization during the production of drug nanocrystals. Journal of Pharmaceutical Sciences, 2009, 98, 2091-2103.	3.3	191
17	Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. European Journal of Pharmaceutical Sciences, 2000, 10, 311-322.	4.0	187
18	Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. European Journal of Pharmaceutical Sciences, 2010, 41, 623-630.	4.0	180

#	Article	IF	Citations
19	Drying of crystalline drug nanosuspensionsâ€"The importance of surface hydrophobicity on dissolution behavior upon redispersion. European Journal of Pharmaceutical Sciences, 2008, 35, 127-135.	4.0	179
20	Characterization of Human Duodenal Fluids in Fasted and Fed State Conditions. Journal of Pharmaceutical Sciences, 2016, 105, 673-681.	3.3	178
21	Nasal vaccination with N-trimethyl chitosan and PLGA based nanoparticles: Nanoparticle characteristics determine quality and strength of the antibody response in mice against the encapsulated antigen. Vaccine, 2010, 28, 6282-6291.	3.8	176
22	Physico-chemical characterization of solid dispersions of temazepam with polyethylene glycol 6000 and PVP K30. International Journal of Pharmaceutics, 1998, 164, 67-80.	5.2	169
23	Evidence for a Polarized Efflux System in Caco-2 Cells Capable of Modulating Cyclosporine A Transport. Biochemical and Biophysical Research Communications, 1993, 197, 360-365.	2.1	165
24	A review of drug solubility in human intestinal fluids: Implications for the prediction of oral absorption. European Journal of Pharmaceutical Sciences, 2014, 57, 322-332.	4.0	159
25	Local immune response to food antigens drives meal-induced abdominal pain. Nature, 2021, 590, 151-156.	27.8	153
26	Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica, 2010, 40, 163-176.	1.1	148
27	Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. International Journal of Pharmaceutics, 2002, 232, 183-192.	5.2	146
28	Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review. European Journal of Pharmaceutical Sciences, 2019, 134, 153-175.	4.0	146
29	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 3479-3487.	6.1	144
30	Impact of gastrointestinal physiology on drug absorption in special populationsâ€"â€“An UNGAP review. European Journal of Pharmaceutical Sciences, 2020, 147, 105280.	4.0	142
31	Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. International Journal of Pharmaceutics, 2004, 274, 221-232.	5.2	141
32	Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. Journal of Pharmacy and Pharmacology, 2010, 58, 1079-1089.	2.4	140
33	Supersaturating Drug Delivery Systems: Fast is Not Necessarily Good Enough. Journal of Pharmaceutical Sciences, 2012, 101, 7-9.	3.3	140
34	Drug permeability profiling using cell-free permeation tools: Overview and applications. European Journal of Pharmaceutical Sciences, 2018, 119, 219-233.	4.0	139
35	Impact of gastrointestinal tract variability on oral drug absorption and pharmacokinetics: An UNGAP review. European Journal of Pharmaceutical Sciences, 2021, 162, 105812.	4.0	137
36	Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice. Antimicrobial Agents and Chemotherapy, 1998, 42, 1568-1573.	3.2	135

#	Article	IF	Citations
37	In vivo, in vitro and in silico methods for small molecule transfer across the BBB. Journal of Pharmaceutical Sciences, 2009, 98, 4429-4468.	3.3	128
38	Excipient-Mediated Supersaturation Stabilization in Human Intestinal Fluids. Molecular Pharmaceutics, 2011, 8, 564-570.	4.6	119
39	Characterization of physico-chemical properties and pharmaceutical performance of sucrose co-freezeâ€“dried solid nanoparticulate powders of the anti-HIV agent loviride prepared by media milling. International Journal of Pharmaceutics, 2007, 338, 198-206.	5.2	118
40	In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3. Drug Metabolism and Disposition, 2010, 38, 25-31.	3.3	115
41	Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole. Clinical Pharmacokinetics, 2011, 50, 725-734.	3.5	114
42	Postprandial Evolution in Composition and Characteristics of Human Duodenal Fluids in Different Nutritional States. Journal of Pharmaceutical Sciences, 2009, 98, 1177-1192.	3.3	112
43	Combined use of ordered mesoporous silica and precipitation inhibitors for improved oral absorption of the poorly soluble weak base itraconazole. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 75, 354-365.	4.3	111
44	Self-Assembly of Cyclodextrins and Their Complexes in Aqueous Solutions. Journal of Pharmaceutical Sciences, 2016, 105, 2556-2569.	3.3	111
45	Structure-Based Identification of OATP1B1/3 Inhibitors. Molecular Pharmacology, 2013, 83, 1257-1267.	2.3	110
46	Sandwich-cultured hepatocytes: utility forin vitroexploration of hepatobiliary drug disposition and drug-induced hepatotoxicity. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 589-616.	3.3	110
47	Postprandial Changes in Solubilizing Capacity of Human Intestinal Fluids for BCS Class II Drugs. Pharmaceutical Research, 2009, 26, 1456-1466.	3.5	109
48	Drug precipitationâ€“permeation interplay: Supersaturation in an absorptive environment. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 82, 424-428.	4.3	107
49	The Influence of CKD on Colonic Microbial Metabolism. Journal of the American Society of Nephrology: JASN, 2016, 27, 1389-1399.	6.1	106
50	Use of Azo Polymers for Colon-Specific Drug Delivery. Journal of Pharmaceutical Sciences, 1997, 86, 1321-1327.	3.3	103
51	The use of human nasal in vitro cell systems during drug discovery and development. Toxicology in Vitro, 2005, 19, 107-122.	2.4	102
52	Investigation of thermal properties of glassy itraconazole: identification of a monotropic mesophase. Thermochimica Acta, 2001, 376, 175-181.	2.7	100
53	Solubility Increases Associated with Crystalline Drug Nanoparticles: Methodologies and Significance. Molecular Pharmaceutics, 2010, 7, 1858-1870.	4.6	100
54	Thiolated chitosan nanoparticles for the nasal administration of leuprolide: Bioavailability and pharmacokinetic characterization. International Journal of Pharmaceutics, 2012, 428, 164-170.	5.2	100

#	Article	IF	Citations
55	Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids. European Journal of Pharmaceutical Sciences, 2011, 43, 260-269.	4.0	97
56	Metabolism of stevioside in pigs and intestinal absorption characteristics of stevioside, rebaudioside A and steviol. Food and Chemical Toxicology, 2003, 41, 1599-1607.	3.6	96
57	Biological, Pharmaceutical, and Analytical Considerations with Respect to the Transport Media Used in the Absorption Screening System, Caco-2. Journal of Pharmaceutical Sciences, 2003, 92, 1545-1558.	3.3	93
58	Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 495-502.	4.3	92
59	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. Journal of Pharmaceutical Sciences, 2016, 105, 2677-2684.	3.3	92
60	Oral biopharmaceutics tools â€“ Time for a new initiative â€“ An introduction to the IMI project OrBiTo. European Journal of Pharmaceutical Sciences, 2014, 57, 292-299.	4.0	91
61	In vitro models for the prediction of in vivo performance of oral dosage forms: Recent progress from partnership through the IMI OrBiTo collaboration. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 70-83.	4.3	91
62	The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine, 2021, 72, 103595.	6.1	91
63	Napsamycins, new Pseudomonas active antibiotics of the mureidomycin family from Streptomyces sp. HIL Y-82, 11372.. Journal of Antibiotics, 1994, 47, 595-598.	2.0	88
64	Drug Supersaturation in Simulated Human Intestinal Fluids Representing Different Nutritional States. Journal of Pharmaceutical Sciences, 2010, 99, 4525-4534.	3.3	88
65	Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: A case study with amprenavir. Journal of Pharmaceutical Sciences, 2006, 95, 372-383.	3.3	87
66	Intestinal Absorption Enhancement of the Ester Prodrug Tenofovir Disoproxil Fumarate through Modulation of the Biochemical Barrier by Defined Ester Mixtures. Drug Metabolism and Disposition, 2002, 30, 924-930.	3.3	86
67	The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nature Communications, 2022, 13, 719.	12.8	86
68	Aging behavior of pharmaceutical formulations of itraconazole on SBA-15 ordered mesoporous silica carrier material. Microporous and Mesoporous Materials, 2010, 130, 154-161.	4.4	85
69	Food-dependent disintegration of immediate release fosamprenavir tablets: In vitro evaluation using magnetic resonance imaging and a dynamic gastrointestinal system. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 77, 313-319.	4.3	84
70	Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network. Advanced Drug Delivery Reviews, 2021, 171, 289-331.	13.7	84
71	Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes. Drug Metabolism and Disposition, 2008, 36, 1119-1125.	3.3	82
72	Gastrointestinal behavior of nano- and microsized fenofibrate: In vivo evaluation in man and in vitro simulation by assessment of the permeation potential. European Journal of Pharmaceutical Sciences, 2015, 77, 40-47.	4.0	82

#	Article	IF	Citations
73	Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. International Journal of Pharmaceutics, 2017, 519, 79-97.	5.2	81
74	Ordered mesoporous silica induces pH-independent supersaturation of the basic low solubility compound itraconazole resulting in enhanced transepithelial transport. International Journal of Pharmaceutics, 2008, 357, 169-179.	5.2	79
75	Hepatocyte-based in vitro model for assessment of drug-induced cholestasis. Toxicology and Applied Pharmacology, 2014, 274, 124-136.	2.8	79
76	Microcrystalline cellulose, a useful alternative for sucrose as a matrix former during freeze-drying of drug nanosuspensions â€“ A case study with itraconazole. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 590-596.	4.3	78
77	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. PLoS ONE, 2015, 10, e0140820.	2.5	77
78	Incomplete Desorption of Liquid Excipients Reduces the in Vitro and in Vivo Performance of Self-Emulsifying Drug Delivery Systems Solidified by Adsorption onto an Inorganic Mesoporous Carrier. Molecular Pharmaceutics, 2012, 9, 2750-2760.	4.6	76
79	Sodium fluorescein is a probe substrate for hepatic drug transport mediated by OATP1B1 and OATP1B3. Journal of Pharmaceutical Sciences, 2011, 100, 5018-5030.	3.3	74
80	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. PLoS ONE, 2016, 11, e0153893.	2.5	74
81	The dynamic gastric environment and its impact on drug and formulation behaviour. European Journal of Pharmaceutical Sciences, 2017, 96, 207-231.	4.0	73
82	Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica, 2005, 35, 1055-1066.	1.1	72
83	Classification of the Crystallization Behavior of Amorphous Active Pharmaceutical Ingredients in Aqueous Environments. Pharmaceutical Research, 2014, 31, 969-982.	3.5	71
84	Inulin hydrogels as carriers for colonic drug targeting: I. Synthesis and characterization of methacrylated inulin and hydrogel formation. Pharmaceutical Research, 1997, 14, 1730-1737.	3.5	69
85	Improvement of the dissolution rate of artemisinin by means of supercritical fluid technology and solid dispersions. International Journal of Pharmaceutics, 2003, 254, 173-181.	5.2	69
86	The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. Peptides, 2008, 29, 1312-1320.	2.4	69
87	Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study. Molecular Pharmaceutics, 2017, 14, 4192-4201.	4.6	69
88	Preoperative administration of the 5-HT4 receptor agonist prucalopride reduces intestinal inflammation and shortens postoperative ileus via cholinergic enteric neurons. Gut, 2019, 68, 1406-1416.	12.1	69
89	Transport of Artemisinin and Sodium Artesunate in Caco-2 Intestinal Epithelial Cells. Journal of Pharmaceutical Sciences, 1996, 85, 577-579.	3.3	68
90	Novel generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early Drug Discovery. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 847, 182-187.	2.3	68

#	Article	IF	Citations
91	Characterization of glassy itraconazole: a comparative study of its molecular mobility below Tg with that of structural analogues using MTDSC. International Journal of Pharmaceutics, 2001, 213, 163-173.	5.2	67
92	The effect of food components on the absorption of P-gp substrates: a review. Journal of Pharmacy and Pharmacology, 2010, 55, 153-162.	2.4	67
93	Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. European Journal of Pharmaceutical Sciences, 2010, 39, 15-22.	4.0	67
94	In Vitro Evaluation of Viability, Integrity, and Inflammation in Genital Epithelia upon Exposure to Pharmaceutical Excipients and Candidate Microbicides. Antimicrobial Agents and Chemotherapy, 2010, 54, 5105-5114.	3.2	65
95	Inulin hydrogels. I. Dynamic and equilibrium swelling properties. International Journal of Pharmaceutics, 1998, 172, 127-135.	5.2	64
96	Alternative matrix formers for nanosuspension solidification: Dissolution performance and X-ray microanalysis as an evaluation tool for powder dispersion. European Journal of Pharmaceutical Sciences, 2008, 35, 344-353.	4.0	63
97	Gastrointestinal transfer: In vivo evaluation and implementation in in vitro and in silico predictive tools. European Journal of Pharmaceutical Sciences, 2014, 63, 233-242.	4.0	63
98	In situ perfusion in rodents to explore intestinal drug absorption: Challenges and opportunities. International Journal of Pharmaceutics, 2015, 478, 665-681.	5.2	63
99	In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: Illustration of intraluminal supersaturation. International Journal of Pharmaceutics, 2007, 336, 302-309.	5.2	62
100	Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 90, 1-7.	4.3	62
101	Higher clearance of micafungin in neonates compared with adults: role of ageâ€dependent micafungin serum binding. Biopharmaceutics and Drug Disposition, 2011, 32, 222-232.	1.9	61
102	Title is missing!. Magyar AprÃ³vad KÃ¶zlemÃ©nyek, 2002, 68, 591-601.	1.4	60
103	An in vitro biorelevant gastrointestinal transfer (BioGIT) system for forecasting concentrations in the fasted upper small intestine: Design, implementation, and evaluation. European Journal of Pharmaceutical Sciences, 2016, 82, 106-114.	4.0	60
104	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1525-1533.	4.5	59
105	In Silico Modeling Approach for the Evaluation of Gastrointestinal Dissolution, Supersaturation, and Precipitation of Posaconazole. Molecular Pharmaceutics, 2017, 14, 4321-4333.	4.6	59
106	Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. International Journal of Pharmaceutics, 1998, 166, 45-53.	5.2	58
107	Use of Caco-2 cells and LC/MS/MS to screen a peptide combinatorial library for permeable structures. International Journal of Pharmaceutics, 1999, 177, 103-115.	5.2	58
108	Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. European Journal of Pharmaceutical Sciences, 2009, 38, 479-488.	4.0	58

#	Article	IF	Citations
109	Iron Deficiency After Roux-en-Y Gastric Bypass: Insufficient Iron Absorption from Oral Iron Supplements. Obesity Surgery, 2014, 24, 56-61.	2.1	58
110	Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971pÂ® and carboxymethylcellulose. Journal of Controlled Release, 2000, 68, 207-214.	9.9	57
111	Supersaturation in human gastric fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 184-189.	4.3	57
112	Metabolism, Protein Binding, and Renal Clearance of Microbiotaâ€“Derived p-Cresol in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1136-1144.	4.5	57
113	Lipid-Based Formulations Solidified Via Adsorption onto the Mesoporous Carrier NeusilinÂ® US2: Effect of Drug Type and Formulation Composition on In Vitro Pharmaceutical Performance. Journal of Pharmaceutical Sciences, 2014, 103, 1734-1746.	3.3	56
114	In Vitro Investigation of the Hepatobiliary Disposition Mechanisms of the Antifungal Agent Micafungin in Humans and Rats. Drug Metabolism and Disposition, 2010, 38, 1848-1856.	3.3	55
115	Proton Pump Inhibitors Reduce Duodenal Eosinophilia, Mast Cells, and Permeability in Patients With Functional Dyspepsia. Gastroenterology, 2021, 160, 1521-1531.e9.	1.3	55
116	Determination of OATP-, NTCP- and OCT-mediated substrate uptake activities in individual and pooled batches of cryopreserved human hepatocytes. European Journal of Pharmaceutical Sciences, 2011, 43, 297-307.	4.0	54
117	Synthesis and characterisation of inulin-azo hydrogels designed for colon targeting. International Journal of Pharmaceutics, 2001, 213, 143-152.	5.2	53
118	Species-dependent and site-specific intestinal metabolism of ester prodrugs. International Journal of Pharmaceutics, 2000, 205, 93-100.	5.2	52
119	Downscaling Drug Nanosuspension Production: Processing Aspects and Physicochemical Characterization. AAPS PharmSciTech, 2009, 10, 44-53.	3.3	52
120	The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate. International Journal of Pharmaceutics, 2011, 414, 118-124.	5.2	52
121	Boosting of HIV Protease Inhibitors by Ritonavir in the Intestine: The Relative Role of Cytochrome P450 and P-Glycoprotein Inhibition Based on Caco-2 Monolayers versus In Situ Intestinal Perfusion in Mice. Drug Metabolism and Disposition, 2012, 40, 1473-1477.	3.3	52
122	Itraconazole/TPGS/AerosilÂ®200 solid dispersions. European Journal of Pharmaceutical Sciences, 2009, 38, 270-278.	4.0	50
123	In-vitro nasal drug delivery studies: comparison of derivatised, fibrillar and polymerised collagen matrix-based human nasal primary culture systems for nasal drug delivery studies. Journal of Pharmacy and Pharmacology, 2010, 53, 1447-1456.	2.4	50
124	Iron deficiency after bariatric surgery: what is the real problem?. Proceedings of the Nutrition Society, 2018, 77, 445-455.	1.0	50
125	In vitrointestinal transport and antihypertensive activity of ACE inhibitory pea and whey digests. International Journal of Food Sciences and Nutrition, 2005, 56, 415-430.	2.8	49
126	An In-Depth View into Human Intestinal Fluid Colloids: Intersubject Variability in Relation to Composition. Molecular Pharmaceutics, 2016, 13, 3484-3493.	4.6	49

#	Article	IF	Citations
127	Gastrointestinal dissolution, supersaturation and precipitation of the weak base indinavir in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 109, 122-129.	4.3	49
128	Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass. The Lancet Gastroenterology and Hepatology, 2021, 6, 225-237.	8.1	49
129	Transport, uptake, and metabolism of the bis(pivaloyloxymethyl)-ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine in an in vitro cell culture system of the intestinal mucosa (Caco-2). Pharmaceutical Research, 1997, 14, 492-496.	3.5	48
130	Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. BMC Nephrology, 2014, 15, 87.	1.8	48
131	Parallel Monitoring of Plasma and Intraluminal Drug Concentrations in Man After Oral Administration of Fosamprenavir in the Fasted and Fed State. Pharmaceutical Research, 2007, 24, 1862-1869.	3.5	47
132	Application of PAMPA-models to predict BBB permeability including efflux ratio, plasma protein binding and physicochemical parameters. International Journal of Pharmaceutics, 2010, 395, 182-197.	5.2	46
133	Inulin hydrogels. II. In vitro degradation study. International Journal of Pharmaceutics, 1998, 172, 137-145.	5.2	45
134	HPLC with programmed wavelength fluorescence detection for the simultaneous determination of marker compounds of integrity and P-gp functionality in the Caco-2 intestinal absorption model. Journal of Pharmaceutical and Biomedical Analysis, 2004, 34, 971-978.	2.8	44
135	High-speed digital imaging method for ciliary beat frequency measurement. Journal of Pharmacy and Pharmacology, 2010, 57, 521-526.	2.4	44
136	Stereoselective Pharmacokinetic Properties of Chloroquine and De-Ethyl-Chloroquine in Humans. Clinical Pharmacokinetics, 1993, 24, 259-269.	3.5	43
137	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. Journal of Pharmaceutical Sciences, 2016, 105, 2904-2912.	3.3	43
138	Safety assessment of selected cyclodextrins â€" effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis. International Journal of Pharmaceutics, 2000, 193, 219-226.	5.2	42
139	Evaluation of fasted and fed state simulated and human intestinal fluids as solvent system in the Ussing chambers model to explore food effects on intestinal permeability. International Journal of Pharmaceutics, 2015, 478, 736-744.	5.2	42
140	Micronutrient intake, from diet and supplements, and association with status markers in pre- and post-RYGB patients. Clinical Nutrition, 2017, 36, 1175-1181.	5.0	42
141	Usefulness of a novel Caco-2 cell perfusion system. I. in vitro prediction of the absorption potential of passively diffused compounds. Journal of Pharmaceutical Sciences, 2004, 93, 2507-2521.	3.3	41
142	Tunability of Pore Diameter and Particle Size of Amorphous Microporous Silica for Diffusive Controlled Release of Drug Compounds. Journal of Physical Chemistry C, 2007, 111, 13404-13409.	3.1	41
143	Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. European Journal of Pharmaceutical Sciences, 2013, 49, 27-32.	4.0	41
144	Human and simulated intestinal fluids as solvent systems to explore food effects on intestinal solubility and permeability. European Journal of Pharmaceutical Sciences, 2014, 63, 178-186.	4.0	41

#	Article	IF	Citations
145	Confocal Imaging with a Fluorescent Bile Acid Analogue Closely Mimicking Hepatic Taurocholate Disposition. Journal of Pharmaceutical Sciences, 2014, 103, 1872-1881.	3.3	41
146	Molecular organization of hydrophobic molecules and co-adsorbed water in SBA-15 ordered mesoporous silica material. Physical Chemistry Chemical Physics, 2011, 13, 2706-2713.	2.8	40
147	A liquid chromatography â€“ tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. Analytica Chimica Acta, 2016, 936, 149-156.	5.4	40
148	Gastrointestinal Behavior of Weakly Acidic BCS Class II Drugs in Manâ€"Case Study of Diclofenac Potassium. Journal of Pharmaceutical Sciences, 2016, 105, 687-696.	3.3	40
149	Assessment of Passive Intestinal Permeability Using an Artificial Membrane Insert System. Journal of Pharmaceutical Sciences, 2018, 107, 250-256.	3.3	40
150	Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids. Molecular Pharmaceutics, 2019, 16, 5042-5053.	4.6	40
151	In vivo evaluation of xanthan gum as a potential excipient for oral controlled-release matrix tablet formulation. International Journal of Pharmaceutics, 1998, 169, 105-113.	5.2	39
152	Potential of amorphous microporous silica for ibuprofen controlled release. International Journal of Pharmaceutics, 2010, 397, 84-91.	5.2	39
153	Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: Role of glycine conjugates. Toxicology in Vitro, 2014, 28, 218-230.	2.4	39
154	Hydration Changes Implicated in the Remarkable Temperature-Dependent Membrane Permeation of Cyclosporin A. Biochemistry, 2000, 39, 7621-7630.	2.5	37
155	INTESTINAL PERFUSION WITH MESENTERIC BLOOD SAMPLING IN WILD-TYPE AND KNOCKOUT MICE. Drug Metabolism and Disposition, 2009, 37, 1334-1337.	3.3	36
156	In Situ Intestinal Perfusion in Knockout Mice Demonstrates Inhibition of Intestinal P-Glycoprotein by Ritonavir Causing Increased Darunavir Absorption. Drug Metabolism and Disposition, 2010, 38, 1407-1410.	3.3	36
157	The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man. Journal of Pharmaceutical Sciences, 2016, 105, 2974-2981.	3.3	36
158	Bile Salt Micelles and Phospholipid Vesicles Present in Simulated and Human Intestinal Fluids: Structural Analysis by Flow Fieldâ€"Flow Fractionation/Multiangle Laser Light Scattering. Journal of Pharmaceutical Sciences, 2016, 105, 2832-2839.	3.3	36
159	Advances in Capillary Electrophoretically Mediated Microanalysis for Onâ€line Enzymatic and Derivatization Reactions. Electrophoresis, 2018, 39, 97-110.	2.4	36
160	Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. Biomedical Applications, 1994, 658, 311-317.	1.7	35
161	Nasal toxicological investigations of Carbopol 971P formulation of apomorphine: effects on ciliary beat frequency of human nasal primary cell culture and in vivo on rabbit nasal mucosa. European Journal of Pharmaceutical Sciences, 2000, 9, 387-396.	4.0	35
162	Melting behavior of pure polyethylene glycol 6000 and polyethylene glycol 6000 in solid dispersions containing diazepam or temazepam: a DSC study. Thermochimica Acta, 2001, 380, 153-164.	2.7	35

#	Article	IF	Citations
163	Inhibitory effect of fruit extracts on P-glycoproteinrelated efflux carriers: an in-vitro screening. Journal of Pharmacy and Pharmacology, 2010, 54, 1213-1219.	2.4	35
164	Preventing release in the acidic environment of the stomach via occlusion in ordered mesoporous silica enhances the absorption of poorly soluble weakly acidic drugs. Journal of Pharmaceutical Sciences, 2011, 100, 4864-4876.	3.3	35
165	The influence of renal transplantation on retained microbialâ€“human co-metabolites. Nephrology Dialysis Transplantation, 2016, 31, 1721-1729.	0.7	35
166	Gastric fluid composition in a paediatric population: Age-dependent changes relevant for gastrointestinal drug disposition. European Journal of Pharmaceutical Sciences, 2018, 123, 301-311.	4.0	35
167	In Vitro, Ex Vivo, and In Situ Intestinal Absorption Characteristics of the Antiviral Ester Prodrug Adefovir Dipivoxil. Journal of Pharmaceutical Sciences, 2000, 89, 1054-1062.	3.3	34
168	Equilibrium drug solubility measurements in 96-well plates reveal similar drug solubilities in phosphate buffer pH 6.8 and human intestinal fluid. International Journal of Pharmaceutics, 2011, 405, 132-136.	5.2	34
169	Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans. European Journal of Pharmaceutical Sciences, 2014, 61, 2-10.	4.0	34
170	Evaluation of fasted state human intestinal fluid as apical solvent system in the Caco-2 absorption model and comparison with FaSSIF. European Journal of Pharmaceutical Sciences, 2015, 67, 126-135.	4.0	34
171	Safety-assessment of 3-methoxyquercetin as an antirhinoviral compound for nasal application: effect on ciliary beat frequency. International Journal of Pharmaceutics, 2003, 263, 95-103.	5.2	33
172	Effect of preservatives on ciliary beat frequency in human nasal epithelial cell culture: Single versus multiple exposure. International Journal of Pharmaceutics, 2007, 338, 64-69.	5.2	33
173	Pharmacokinetics of Posaconazole Oral Suspension in Children Dosed According to Body Surface Area. Pediatric Infectious Disease Journal, 2016, 35, 183-188.	2.0	33
174	Biorelevant dissolution testing of a weak base: Interlaboratory reproducibility and investigation of parameters controlling in vitro precipitation. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 140, 141-148.	4.3	33
175	Toxicological investigations of the effects carboxymethylcellulose on ciliary beat frequency of human nasal epithelial cells in primary suspension culture and in vivo on rabbit nasal mucosa. International Journal of Pharmaceutics, 2000, 205, 43-51.	5.2	32
176	New bis(SATE) prodrug of AZT 5â€²â€monophosphate: In vitro antiâ€HIV activity, stability, and potential oral absorption. Journal of Pharmaceutical Sciences, 2001, 90, 448-463.	3.3	32
177	P-glycoprotein attenuating effect of human intestinal fluid. Pharmaceutical Research, 2003, 20, 900-903.	3.5	32
178	MiniCD4 Microbicide Prevents HIV Infection of Human Mucosal Explants and Vaginal Transmission of SHIV162P3 in Cynomolgus Macaques. PLoS Pathogens, 2012, 8, e1003071.	4.7	32
179	Intestinal disposition of quercetin and its phase-II metabolites after oral administration in healthy volunteers. Journal of Pharmacy and Pharmacology, 2018, 70, 1002-1008.	2.4	32
180	Cellular Accumulation of Cholyl-Glycylamido-Fluorescein in Sandwich-Cultured Rat Hepatocytes: Kinetic Characterization, Transport Mechanisms, and Effect of Human Immunodeficiency Virus Protease Inhibitors. Drug Metabolism and Disposition, 2008, 36, 1315-1321.	3.3	31

#	Article	IF	Citations
181	Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwichâ€cultured rat and human hepatocytes. Biopharmaceutics and Drug Disposition, 2010, 31, 178-188.	1.9	31
182	In vitro profiling of the vaginal permeation potential of anti-HIV microbicides and the influence of formulation excipients. Antiviral Research, 2012, 96, 226-233.	4.1	31
183	PXR/CYP3A4-Humanized Mice for Studying Drugâ€“Drug Interactions Involving Intestinal P-Glycoprotein. Molecular Pharmaceutics, 2013, 10, 1056-1062.	4.6	31
184	Ethanol concentrations in the human gastrointestinal tract after intake of alcoholic beverages. European Journal of Pharmaceutical Sciences, 2016, 86, 91-95.	4.0	31
185	Identification of phase-II metabolites of flavonoids by liquid chromatographyâ€“ion-mobility spectrometryâ€“mass spectrometry. Analytical and Bioanalytical Chemistry, 2018, 410, 471-482.	3.7	31
186	Effects of pharmaceutical compounds on ciliary beating in human nasal epithelial cells: a comparative study of cell culture models. Pharmaceutical Research, 1999, 16, 1380-1385.	3.5	30
187	In Vitro Screening Models to Assess Intestinal Drug Absorption and Metabolism. , 2008, , 182-215.		30
188	Llama Antibody Fragments Have Good Potential for Application as HIV Type 1 Topical Microbicides. AIDS Research and Human Retroviruses, 2012, 28, 198-205.	1.1	30
189	Gastrointestinal behavior of itraconazole in humans â€“ Part 2: The effect of intraluminal dilution on the performance of a cyclodextrin-based solution. International Journal of Pharmaceutics, 2017, 526, 235-243.	5.2	30
190	The BioGIT System: a Valuable In Vitro Tool to Assess the Impact of Dose and Formulation on Early Exposure to Low Solubility Drugs After Oral Administration. AAPS Journal, 2018, 20, 71.	4.4	30
191	In vitro evaluation of the impact of gastrointestinal transfer on luminal performance of commercially available products of posaconazole and itraconazole using BioGIT. International Journal of Pharmaceutics, 2016, 515, 352-358.	5.2	29
192	Best practices in current models mimicking drug permeability in the gastrointestinal tract - An UNGAP review. European Journal of Pharmaceutical Sciences, 2022, 170, 106098.	4.0	29
193	Medication Cost is Significantly Reduced After Roux-en-Y Gastric Bypass in Obese Patients. Obesity Surgery, 2014, 24, 1896-1903.	2.1	28
194	Gastrointestinal and Systemic Disposition of Diclofenac under Fasted and Fed State Conditions Supporting the Evaluation of in Vitro Predictive Tools. Molecular Pharmaceutics, 2017, 14, 4220-4232.	4.6	28
195	The artificial membrane insert system as predictive tool for formulation performance evaluation. International Journal of Pharmaceutics, 2018, 537, 22-29.	5.2	28
196	Evaluation of the potential of ion pair formation to improve the oral absorption of two potent antiviral compounds, AMD3100 and PMPA. International Journal of Pharmaceutics, 1999, 186, 127-136.	5.2	27
197	Gastrointestinal behavior of itraconazole in humans â€“ Part 1: Supersaturation from a solid dispersion and a cyclodextrin-based solution. International Journal of Pharmaceutics, 2017, 525, 211-217.	5.2	27
198	Altered duodenal bile salt concentration and receptor expression in functional dyspepsia. United European Gastroenterology Journal, 2018, 6, 1347-1355.	3.8	27

#	Article	IF	Citations
199	Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1. Aids, 2001, 15, 2205-2207.	2.2	27
200	Determination of partial solubility parameters of five benzodiazepines in individual solvents. International Journal of Pharmaceutics, 2001, 228, 199-207.	5.2	26
201	Apricot Extract Inhibits the P-gpâ€“Mediated Efflux of Talinolol. Journal of Pharmaceutical Sciences, 2002, 91, 2539-2548.	3.3	26
202	Solubility Profiling of HIV Protease Inhibitors in Human Intestinal Fluids. Journal of Pharmaceutical Sciences, 2013, 102, 3800-3807.	3.3	26
203	Displacement of itraconazole from cyclodextrin complexes in biorelevant media: In vitro evaluation of supersaturation and precipitation behavior. International Journal of Pharmaceutics, 2016, 511, 680-687.	5.2	26
204	In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat. Pharmaceutical Research, 1996, 13, 891-895.	3.5	25
205	Influence of Essential and Fatty Oils on Ciliary Beat Frequency of Human Nasal Epithelial Cells. American Journal of Rhinology & Allergy, 2008, 22, 130-134.	2.2	25
206	Sulfasalazine transport in in-vitro, ex-vivo and in-vivo absorption models: contribution of efflux carriers and their modulation by co-administration of synthetic nature-identical fruit extracts. Journal of Pharmacy and Pharmacology, 2010, 57, 1565-1573.	2.4	25
207	Comparison of the Complexation between Methylprednisolone and Different Cyclodextrins in Solution by 1H-NMR and Molecular Modeling Studies. Journal of Pharmaceutical Sciences, 2010, 99, 3863-3873.	3.3	25
208	Intestinal behavior of the ester prodrug tenofovir DF in humans. International Journal of Pharmaceutics, 2015, 485, 131-137.	5.2	25
209	Drug disposition and modelling before and after gastric bypass: immediate and controlledâ€release metoprolol formulations. British Journal of Clinical Pharmacology, 2015, 80, 1021-1030.	2.4	25
210	Enhanced performance for the analysis of prostaglandins and thromboxanes by liquid chromatography-tandem mass spectrometry using a new atmospheric pressure ionization source. Journal of Chromatography A, 2016, 1440, 260-265.	3.7	25
211	Exploring the link between gastric motility and intragastric drug distribution in man. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 112, 75-84.	4.3	25
212	Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. International Journal of Pharmaceutics, 2002, 234, 113-119.	5.2	24
213	Development and characterization of a solid dispersion film for the vaginal application of the anti-HIV microbicide UAMC01398. International Journal of Pharmaceutics, 2014, 475, 238-244.	5.2	24
214	Drug disposition before and after gastric bypass: fenofibrate and posaconazole. British Journal of Clinical Pharmacology, 2016, 82, 1325-1332.	2.4	24
215	In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. International Journal of Pharmaceutics, 1999, 188, 81-86.	5.2	23
216	Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: an in vitro study. Pharmaceutical Research, 1999, 16, 1035-1040.	3.5	23

#	Article	IF	Citations
217	Specific Antibody Modulates Absorptive Transport and Metabolic Activation of Benzo[a]pyrene across Caco-2 Monolayers. Journal of Pharmacology and Experimental Therapeutics, 2005, 313, 640-646.	2.5	23
218	Phenyl phosphotriester derivatives of AZT: Variations upon the SATE moiety. Bioorganic and Medicinal Chemistry, 2008, 16, 7321-7329.	3.0	23
219	Determination of intraluminal theophylline concentrations after oral intake of an immediate-and a slow-release dosage form. Journal of Pharmacy and Pharmacology, 2010, 57, 987-995.	2.4	23
220	Safety assessment of thiolated polymers: effect on ciliary beat frequency in human nasal epithelial cells. Drug Development and Industrial Pharmacy, 2011, 37, 1455-1462.	2.0	23
221	Duodenal Dysbiosis and Relation to the Efficacy of Proton Pump Inhibitors in Functional Dyspepsia. International Journal of Molecular Sciences, 2021, 22, 13609.	4.1	23
222	Carrier mechanisms involved in the transepithelial transport of bis(POM)-PMEA and its metabolites across Caco-2 monolayers. Pharmaceutical Research, 1998, 15, 1168-1173.	3.5	22
223	Relationship between bile salts, bacterial translocation, and duodenal mucosal integrity in functional dyspepsia. Neurogastroenterology and Motility, 2020, 32, e13788.	3.0	22
224	High-Throughput Study of Phenytoin Solid Dispersions: Formulation Using an Automated Solvent Casting Method, Dissolution Testing, and Scaling-Up. ACS Combinatorial Science, 2008, 10, 637-643.	3.3	21
225	Magnetic field assisted nanoparticle dispersion. Chemical Communications, 2008, , 47-49.	4.1	21
226	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. European Journal of Clinical Pharmacology, 2016, 72, 953-963.	1.9	21
227	Development of a HILIC-MS/MS method for the quantification of histamine and its main metabolites in human urine samples. Talanta, 2020, 220, 121328.	5.5	21
228	Absorption and Intestinal Metabolic Profile of Oleocanthal in Rats. Pharmaceutics, 2020, 12, 134.	4.5	21
229	Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Research, 2014, 101, 113-121.	4.1	20
230	Exploring drug solubility in fasted human intestinal fluid aspirates: Impact of inter-individual variability, sampling site and dilution. International Journal of Pharmaceutics, 2017, 528, 471-484.	5.2	20
231	Growth of Itraconazole Nanofibers in Supersaturated Simulated Intestinal Fluid. Molecular Pharmaceutics, 2010, 7, 905-913.	4.6	19
232	Beneficial effect of antibiotics on ciliary beat frequency of human nasal epithelial cells exposed to bacterial toxins. Journal of Pharmacy and Pharmacology, 2010, 60, 437-443.	2.4	19
233	An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency. Journal of Pharmacy and Pharmacology, 2010, 61, 883-890.	2.4	19
234	HPLC Method for the Determination of Chloroquine and its Main Metabolite in Biological Samples. Journal of Liquid Chromatography and Related Technologies, 1990, 13, 1203-1213.	1.0	18

#	Article	IF	Citations
235	Title is missing!. Magyar AprÃ³vad KÃ¶zlemÃ©nyek, 1999, 57, 493-507.	1.4	18
236	CADA, a Potential Anti-HIV Microbicide that Specifically Targets the Cellular CD4 Receptor. Current HIV Research, 2008, 6, 246-256.	0.5	18
237	Effects of T cell-induced colonic inflammation on epithelial barrier functionâ€. Inflammatory Bowel Diseases, 2010, 16, 1322-1331.	1.9	18
238	Species-Specific Interaction of HIV Protease Inhibitors With Accumulation of Cholyl-Glycylamido-Fluorescein (CGamF) in Sandwich-Cultured Hepatocytes. Journal of Pharmaceutical Sciences, 2010, 99, 2886-2898.	3.3	18
239	In Situ FT-IR Investigation of Etravirine Speciation in Pores of SBA-15 Ordered Mesoporous Silica Material upon Contact with Water. Molecular Pharmaceutics, 2013, 10, 567-573.	4.6	18
240	Recent advances in CE mediated microanalysis for enzymatic and derivatization reactions. Electrophoresis, 2016, 37, 56-65.	2.4	18
241	In vitro and in vivo investigation of the gastrointestinal behavior of simvastatin. International Journal of Pharmaceutics, 2016, 510, 296-303.	5.2	18
242	The impact of guest compounds on cyclodextrin aggregation behavior: A series of structurally related parabens. International Journal of Pharmaceutics, 2017, 529, 442-450.	5.2	18
243	Molecular Dynamics Simulations on Interindividual Variability of Intestinal Fluids: Impact on Drug Solubilization. Molecular Pharmaceutics, 2020, 17, 3837-3844.	4.6	18
244	Unraveling the behavior of oral drug products inside the human gastrointestinal tract using the aspiration technique: History, methodology and applications. European Journal of Pharmaceutical Sciences, 2020, 155, 105517.	4.0	18
245	Drug Disposition in the Lower Gastrointestinal Tract: Targeting and Monitoring. Pharmaceutics, 2021, 13, 161.	4.5	18
246	Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-GelucireÂ® core. Journal of Controlled Release, 2005, 107, 523-536.	9.9	17
247	Validation of a differential in situ perfusion method with mesenteric blood sampling in rats for intestinal drug interaction profiling. Biopharmaceutics and Drug Disposition, 2010, 31, 278-285.	1.9	17
248	Age-Dependent Activity of the Uptake Transporters Ntcp and Oatp1b2 in Male Rat Hepatocytes: From Birth Till Adulthood. Drug Metabolism and Disposition, 2015, 43, 1-8.	3.3	17
249	Clearance Prediction of HIV Protease Inhibitors in Man: Role of Hepatic Uptake. Journal of Pharmaceutical Sciences, 2016, 105, 854-863.	3.3	17
250	Atmospheric Pressure Ionization Using a High Voltage Target Compared to Electrospray Ionization. Journal of the American Society for Mass Spectrometry, 2017, 28, 286-293.	2.8	17
251	The effect of 2-hydroxypropyl-Î²-cyclodextrin on the intestinal permeation through mucus. European Journal of Pharmaceutical Sciences, 2018, 114, 238-244.	4.0	17
252	Human intestinal fluid layer separation: The effect on colloidal structures & solubility of lipophilic compounds. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 104-110.	4.3	17

#	Article	IF	Citations
253	Human intestinal fluid factors affecting intestinal drug permeation in vitro. European Journal of Pharmaceutical Sciences, 2018, 121, 338-346.	4.0	17
254	Development and in vitro evaluation of chloroquine gels as microbicides against HIV-1 infection. Virology, 2008, 378, 306-310.	2.4	16
255	Multidimensional analysis of human intestinal fluid composition. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 153, 226-240.	4.3	16
256	Effect of obesity on gastrointestinal transit, pressure and pH using a wireless motility capsule. European Journal of Pharmaceutics and Biopharmaceutics, 2021, 167, 1-8.	4.3	16
257	Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole. Clinical Pharmacokinetics, 2015, 54, 1151-1160.	3.5	15
258	An atmospheric pressure ionization source using a high voltage target compared to electrospray ionization for the LC/MS analysis of pharmaceutical compounds. Journal of Pharmaceutical and Biomedical Analysis, 2017, 142, 225-231.	2.8	15
259	The Effect of Sparkling Water on Intraluminal Formulation Behavior and Systemic Drug Performance. Journal of Pharmaceutical Sciences, 2017, 106, 2472-2482.	3.3	15
260	Exploring the Effect of Esomeprazole on Gastric and Duodenal Fluid Volumes and Absorption of Ritonavir. Pharmaceutics, 2020, 12, 670.	4.5	15
261	Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated ef?ux. Phytotherapy Research, 2003, 17, 459-464.	5.8	14
262	Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). Journal of Pharmacy and Pharmacology, 2010, 53, 1109-1116.	2.4	14
263	Early identification of availability issues for poorly water-soluble microbicide candidates in biorelevant media: A case study with saquinavir. Antiviral Research, 2011, 91, 217-223.	4.1	14
264	Solubilizing agents in nasal formulations and their effect on ciliary beat frequency. Toxicology in Vitro, 2012, 26, 150-156.	2.4	14
265	Development of thiolated poly(acrylic acid) microparticles for the nasal administration of exenatide. Drug Development and Industrial Pharmacy, 2014, 40, 1677-1682.	2.0	14
266	Vaginal Expression of Efflux Transporters and the Potential Impact on the Disposition of Microbicides in Vitro and in Rabbits. Molecular Pharmaceutics, 2014, 11, 4405-4414.	4.6	14
267	Trapping magnetic nanoparticles for in-line capillary electrophoresis in a liquid based capillary coolant system. Talanta, 2017, 164, 148-153.	5.5	14
268	An improved design to capture magnetic microparticles for capillary electrophoresis based immobilized microenzyme reactors. Electrophoresis, 2018, 39, 981-988.	2.4	14
269	The effect of chitosan on the bioaccessibility and intestinal permeability of acyclovir. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 147-155.	4.3	14
270	Gastric and Duodenal Diclofenac Concentrations in Healthy Volunteers after Intake of the FDA Standard Meal: In Vivo Observations and in Vitro Explorations. Molecular Pharmaceutics, 2019, 16, 573-582.	4.6	14

#	Article	IF	Citations
271	The effect of reduced gastric acid secretion on the gastrointestinal disposition of a ritonavir amorphous solid dispersion in fasted healthy volunteers: an in vivo - in vitro investigation.. European Journal of Pharmaceutical Sciences, 2020, 151, 105377.	4.0	14
272	Biorelevant Two-Stage InÂVitro Testing for rDCS Classification and in PBPK Modelingâ€“Case Example Ritonavir. Journal of Pharmaceutical Sciences, 2020, 109, 2512-2526.	3.3	14
273	Co-existing colloidal phases of human duodenal aspirates: Intraindividual fluctuations and interindividual variability in relation to molecular composition. Journal of Pharmaceutical and Biomedical Analysis, 2019, 170, 22-29.	2.8	13
274	Codeine delays gastric emptying through inhibition of gastric motility as assessed with a novel diagnostic intragastric balloon catheter. Neurogastroenterology and Motility, 2020, 32, e13733.	3.0	13
275	Determination of Artesunate by Capillary Electrophoresis with Low UV Detection and Possible Applications to Analogues. Journal of Chromatographic Science, 1996, 34, 276-281.	1.4	12
276	Application of the thermodynamics of mobile order and disorder to explain the solubility of temazepam in aqueous solutions of polyethylene glycol 6000. International Journal of Pharmaceutics, 1998, 164, 81-89.	5.2	12
277	The Influence of Nebulized Drugs on Nasal Ciliary Activity. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2016, 29, 378-385.	1.4	12
278	Linking the concentrations of itraconazole and 2-hydroxypropyl-Î²-cyclodextrin in human intestinal fluids after oral intake of SporanoxÂ®. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 132, 231-236.	4.3	12
279	Insight into the colonic disposition of celecoxib in humans. European Journal of Pharmaceutical Sciences, 2020, 145, 105242.	4.0	12
280	Practical and operational considerations related to paediatric oral drug formulation: An industry survey. International Journal of Pharmaceutics, 2022, 618, 121670.	5.2	12
281	Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective. European Journal of Pharmaceutical Sciences, 2022, 172, 106100.	4.0	12
282	Stable ciliary activity in human nasal epithelial cells grown in a perfusion system. International Journal of Pharmaceutics, 2005, 292, 157-168.	5.2	11
283	Biochemical characterization of malate synthase G of P. aeruginosa. BMC Biochemistry, 2009, 10, 20.	4.4	11
284	Site dependent intestinal absorption of darunavir and its interaction with ketoconazole. European Journal of Pharmaceutical Sciences, 2013, 49, 51-56.	4.0	11
285	Straightforward entry to pyrido[2,3-d]pyrimidine-2,4(1H,3H)-diones and their ADME properties. Bioorganic and Medicinal Chemistry, 2014, 22, 3947-3956.	3.0	11
286	Development of enteric-coated fixed dose combinations of amorphous solid dispersions of ezetimibe and lovastatin: Investigation of formulation and process parameters. International Journal of Pharmaceutics, 2017, 520, 49-58.	5.2	11
287	Evaluation of real-life dosing of oral medicines with respect to fluid and food intake in a Dutch-speaking population. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 467-474.	1.5	11
288	Development of a sensitive and quantitative UHPLC-MS/MS method to study the whole-body uptake of pharmaceuticals in zebrafish. Talanta, 2017, 174, 780-788.	5.5	11

#	Article	IF	Citations
289	The influence of gastric motility on the intraluminal behavior of fosamprenavir. European Journal of Pharmaceutical Sciences, 2020, 142, 105117.	4.0	11
290	Exploring the impact of real-life dosing conditions on intraluminal and systemic concentrations of atazanavir in parallel with gastric motility recording in healthy subjects. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 150, 66-76.	4.3	11
291	Comparison of the disposition of ester prodrugs of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine [PMEA] in Caco-2 monolayers. Pharmaceutical Research, 1998, 15, 239-245.	3.5	10
292	Verapamil hepatic clearance in four preclinical rat models: towards activityâ€based scaling. Biopharmaceutics and Drug Disposition, 2015, 36, 462-480.	1.9	10
293	Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine. Pharmaceutical Research, 2017, 34, 2336-2348.	3.5	10
294	Exploring gastric drug absorption in fasted and fed state rats. International Journal of Pharmaceutics, 2018, 548, 636-641.	5.2	10
295	Transplacental Distribution of Chloroquine in Sheep. Developmental Pharmacology and Therapeutics, 1991, 17, 191-199.	0.2	9
296	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating Systemâ€Based Liver Dialysis. Artificial Organs, 2012, 36, 29-41.	1.9	9
297	Biopharmaceutical profiling of a pyrido[4,3-d] pyrimidine compound library. International Journal of Pharmaceutics, 2013, 455, 19-30.	5.2	9
298	Association between duodenal bile salts and gastric emptying in patients with functional dyspepsia. Gut, 2021, 70, 2208.2-2210.	12.1	9
299	Insight into the Colonic Disposition of Sulindac in Humans. Journal of Pharmaceutical Sciences, 2021, 110, 259-267.	3.3	9
300	Codeine induces increased resistance at the esophagogastric junction but has no effect on motility and bolus flow in the pharynx and upper esophageal sphincter in healthy volunteers: A randomized, doubleâ€blind, placeboâ€controlled, crossâ€over trial. Neurogastroenterology and Motility, 2021, 33, e14041.	3.0	9
301	Fasted intestinal solubility limits and distributions applied to the biopharmaceutics and developability classification systems. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 160-169.	4.3	9
302	Thermal characterization of the antiviral drug UC-781 and stability of its glass. Thermochimica Acta, 2001, 366, 61-69.	2.7	8
303	Chiral capillary electrophoretic method for quantification of apomorphine. Journal of Chromatography A, 2004, 1049, 195-203.	3.7	8
304	Uptake and Transport Characteristics of Chloroquine in an In-vitro Cell Culture System of the Intestinal Mucosa, Caco-2. Journal of Pharmacy and Pharmacology, 2011, 48, 277-280.	2.4	8
305	Unbound Ritonavir Concentrations in Rat and Human Hepatocytes. Journal of Pharmaceutical Sciences, 2015, 104, 2378-2387.	3.3	8
306	Application of the Gastrointestinal Simulator (GIS) Coupled with In Silico Modeling to Measure the Impact of Coca-ColaÂ® on the Luminal and Systemic Behavior of Loratadine (BCS Class 2b). Pharmaceutics, 2020, 12, 566.	4.5	8

#	Article	IF	Citations
307	Crystallization Kinetics in Fasted-State Simulated and Aspirated Human Intestinal Fluids. Crystal Growth and Design, 2021, 21, 2807-2820.	3.0	8
308	HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect. Antiviral Research, 2022, 202, 105311.	4.1	8
309	Diminished sedation during diazepam treatment for chloroquine intoxication. International Journal of Clinical Pharmacy, 1993, 15, 83-85.	1.4	7
310	Comparison between 2-hydroxypropyl-Î²-cyclodextrin and 2-hydroxypropyl-Î³-cyclodextrin for inclusion complex formation with danazol. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2011, 71, 137-147.	1.6	7
311	Intestinal phase-II metabolism of quercetin in HT29 cells, 3D human intestinal tissues and in healthy volunteers: a qualitative comparison using LC-IMS-MS and LC-HRMS. Xenobiotica, 2019, 49, 945-952.	1.1	7
312	Metabonomics and Drug Development. Methods in Molecular Biology, 2015, 1277, 195-207.	0.9	7
313	Determination of Chloroquine and Desethylchloroquine in Biological Samples Using Perfusion Chromatography and Fluorescence Detection. Journal of Liquid Chromatography and Related Technologies, 1997, 20, 1103-1113.	1.0	6
314	Binary Phase Diagram of Tetraethyl Orthosilicate and Carbon Dioxide. Journal of Chemical & Engineering Data, 2008, 53, 2573-2575.	1.9	6
315	Ordered Mesoporous Silica for the Delivery of Poorly Soluble Drugs. , 2011, , 203-219.		6
316	One drop chemical derivatization â€“ DESIâ€MS analysis for metabolite structure identification. Journal of Mass Spectrometry, 2015, 50, 871-878.	1.6	6
317	Barriers in the Approach of Obese Patients Undergoing Bariatric Surgery in Flemish Hospitals. Obesity Surgery, 2015, 25, 2153-2158.	2.1	6
318	Evaluation of immobilized hFMO3 on magnetic nanoparticles by capillary zone electrophoresis. Bioanalysis, 2017, 9, 289-296.	1.5	6
319	Extra collagen overlay prolongs the differentiated phenotype in sandwich-cultured rat hepatocytes. Journal of Pharmacological and Toxicological Methods, 2018, 90, 31-38.	0.7	6
320	Immobilizing sulfotransferase 1A1 on magnetic microparticles and their evaluation using capillary electrophoresis. Electrophoresis, 2019, 40, 2271-2276.	2.4	6
321	Biopredictive in vitro testing methods to assess intestinal drug absorption from supersaturating dosage forms. Journal of Drug Delivery Science and Technology, 2020, 56, 101275.	3.0	6
322	A Microassay Method for the Determination of Theophylline in Biological Samples Using HPLC with Electrochemical Detection. Journal of Liquid Chromatography and Related Technologies, 1992, 15, 1303-1313.	1.0	5
323	Peptidyl Dipeptidase A-Catalyzed Metabolism of Delta Sleep-Inducing Peptide in Bovine Brain Microvessel Endothelial Cells: A Cell Culture Model of the Blood-Brain Barrier. Biochemical and Biophysical Research Communications, 1995, 210, 987-994.	2.1	5
324	Capillary zone electrophoresis method development for the analysis of Hippeastrum hybrid agglutinin samples. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 563-567.	2.3	5

#	Article	IF	Citations
325	Hepatic Clearance Prediction of Nine Human Immunodeficiency Virus Protease Inhibitors in Rat. Journal of Pharmaceutical Sciences, 2016, 105, 846-853.	3.3	5
326	Transport-Metabolism Interplay of Atazanavir in Rat Hepatocytes. Drug Metabolism and Disposition, 2016, 44, 389-397.	3.3	5
327	Effect of Cryopreservation on Enzyme and Transporter Activities in Suspended and Sandwich Cultured Rat Hepatocytes. AAPS Journal, 2018, 20, 33.	4.4	5
328	Chloroquine, an Anti-Malaria Drug as Effective Prevention for Hantavirus Infections. Frontiers in Cellular and Infection Microbiology, 2021, 11, 580532.	3.9	5
329	Screening protocol for identifying inorganic oxides with anti-oxidant and pro-oxidant activity for biomedical, environmental and food preservation applications. RSC Advances, 2013, 3, 900-909.	3.6	4
330	The Use of Supersaturation for the Vaginal Application of Microbicides: A Case Study with Dapivirine. Journal of Pharmaceutical Sciences, 2014, 103, 3696-3703.	3.3	4
331	Synthesis of 1-substituted epibatidine analogues and their in vitro and in vivo evaluation as Î±₄Î²₂ nicotinic acetylcholine receptor ligands. RSC Advances, 2013, 4, 2226-2234.	3.6	4
332	A Tribute to Ronald T. Borchardtâ€"Teacher, Mentor, Scientist, Colleague, Leader, Friend, and Family Man. Journal of Pharmaceutical Sciences, 2016, 105, 370-385.	3.3	4
333	Effect of Age on The Hepatocellularity Number for Wistar rats. Drug Metabolism and Disposition, 2016, 44, 944-947.	3.3	4
334	Inter-Subject Variability in OCT1 Activity in 27 Batches of Cryopreserved Human Hepatocytes and Association with OCT1 mRNA Expression and Genotype. Pharmaceutical Research, 2017, 34, 1309-1319.	3.5	4
335	Flexible nano- and microliter injections on a single liquid chromatographyâ€"mass spectrometry system: Minimizing sample preparation and maximizing linear dynamic range. Journal of Chromatography A, 2017, 1524, 101-107.	3.7	4
336	Gastric and Duodenal Ethanol Concentrations after Intake of Alcoholic Beverages in Postprandial Conditions. Molecular Pharmaceutics, 2017, 14, 4202-4208.	4.6	4
337	Predicting iron absorption from an effervescent iron supplement in obese patients before and after Roux-en-Y gastric bypass: a preliminary study. Journal of Trace Elements in Medicine and Biology, 2019, 52, 68-73.	3.0	4
338	Specific contributions of segmental transit times to gut microbiota composition. Gut, 2021, , gutjnl-2021-325916.	12.1	4
339	Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research. Pharmaceutics, 2022, 14, 801.	4.5	4
340	Structured solubility behaviour in bioequivalent fasted simulated intestinal fluids. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 176, 108-121.	4.3	4
341	High Speed HPLC Determination of Bis(Pivaloyloxymethyl)-PMEA and Its Degradation Products, Mono(POM)-PMEA and PMEA. Journal of Liquid Chromatography and Related Technologies, 1996, 19, 2271-2283.	1.0	3
342	Hepatobiliary and intestinal elimination of darunavir in an integrated preclinical rat model. Xenobiotica, 2014, 44, 489-497.	1.1	3

#	Article	IF	Citations
343	Association Between Luminal Bile Salt Content and Duodenal Mucosal Integrity in Funcional Dyspepsia. Gastroenterology, 2017, 152, S167.	1.3	3
344	The effect of esomeprazole on the upper GI tract release and systemic absorption of mesalazine from colon targeted formulations. International Journal of Pharmaceutics, 2022, 619, 121701.	5.2	3
345	Investigating the Mechanisms behind the Positive Food Effect of Abiraterone Acetate: In Vitro and Rat In Situ Studies. Pharmaceutics, 2022, 14, 952.	4.5	3
346	Chloroquine pharmacokinetic data during chronic daily treatment. European Journal of Clinical Pharmacology, 1993, 44, 409-410.	1.9	2
347	Stability of UC-781, in intestinal mucosal homogenates of the rat, rabbit, and pig. Pharmaceutical Research, 1998, 15, 1799-1802.	3.5	2
348	A step further in the SATE mononucleotide prodrug approach. Nucleic Acids Symposium Series, 2008, 52, 539-540.	0.3	2
349	In vitro disposition profiling of heterocyclic compounds. International Journal of Pharmaceutics, 2015, 491, 78-90.	5.2	2
350	Reply to â€œComment on LÃ³pez-Yerena et al. â€˜Absorption and Intestinal Metabolic Profile of Oleocanthal in Ratsâ€™ Pharmaceutics 2020, 12, 134â€• Pharmaceutics, 2020, 12, 1221.	4.5	2
351	Exploring the Impact of Intestinal Fluid Components on the Solubility and Supersaturation of Danazol. Journal of Pharmaceutical Sciences, 2021, 110, 2479-2488.	3.3	2
352	Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare. Frontiers in Medicine, 2021, 8, 480706.	2.6	2
353	The Influence of Fed State Lipolysis Inhibition on the Intraluminal Behaviour and Absorption of Fenofibrate from a Lipid-Based Formulation. Pharmaceutics, 2022, 14, 119.	4.5	2
354	Influence of the composition of in-vitro azo-reducing systems on the degradation kinetics of the model compound amaranth. Journal of Pharmacy and Pharmacology, 2010, 54, 197-203.	2.4	1
355	Editorial: In Memoriam Dr. Marcus Brewster. Journal of Pharmaceutical Sciences, 2014, 103, 3808-3809.	3.3	1
356	An Assessment of Occasional Bio-Inequivalence for BCS1 and BCS3 Drugs: What are the Underlying Reasons?. Journal of Pharmaceutical Sciences, 2021, , .	3.3	1
357	Selection of Solvent Systems for Membrane-, Cell- and Tissue-Based Permeability Assessment. , 2007, , 179-220.		1
358	Orlistat disposition in the human jejunum and the effect of lipolysis inhibition on bile salt concentrations and composition. International Journal of Pharmaceutics, 2022, 621, 121807.	5.2	1
359	THE BELGIAN SOCIETY FOR CELL BIOLOGY.IN VITROMODELS OF ENDOTHELIAL AND EPITHELIAL BARRIERS: DEVELOPMENT, CELL BIOLOGY AND PHARMACOLOGICAL APPLICATIONS 39th ORDINARY MEETING. Cell Biology International, 1997, 21, 511-535.	3.0	0
360	Influence of Neopterin on Ciliary Beat Frequency of Human Nasal Epithelial Cells in vitro. Pteridines, 2008, 19, 79-85.	0.5	0

#	Article	IF	Citations
361	Do Roux-en-Y gastric bypass patients meet the dietary guidelines?. Archives of Public Health, 2014, 72, .	2.4	0
362	FP594TARGETING MICROBIOTA DERIVED UREMIC RETENTION SOLUTES WITH ANTIBIOTICS. Nephrology Dialysis Transplantation, 2015, 30, iii271-iii271.	0.7	0
363	A Tribute to Dr. Marcus E. Brewster. Journal of Pharmaceutical Sciences, 2016, 105, 2466-2467.	3.3	0
364	The Effect of the Acid Pocket of Healthy Volunteers and Gerd Patients on Epithelial Integrity. Gastroenterology, 2017, 152, S235-S236.	1.3	0
365	Opening the black box: Gastric motility, as assessed by the novel vipun gastric monitoring system, is a surrogate measurement for gastric emptying. Clinical Nutrition, 2018, 37, S34.	5.0	0
366	An improved primary human nasal cell culture for the simultaneous determination of transepithelial transport and ciliary beat frequency. Journal of Pharmacy and Pharmacology, 2009, 61, 883-890.	2.4	0